Azemiglitazone (2-5 μM in blood, p.o for 2-4 weeks) improves insulin sensitivity in striated muscle, adipose tissue, and liver of DIO C57BL/6 mice[6].
Azemiglitazone (2-5 μM in blood, p.o for 2-4 weeks) improves mitochondrial respiratory rate in DIO C57BL/6 mice[6].
Azemiglitazone reduces NASH caused liver injury, prevents (2-5 μM in blood, p.o. for 12 weeks) and reverses (2-5 μM in blood, p.o. for 3 weeks) stellate cells activation and fibrosis in HTF-C diet feeding C57BL6/J mice[4].
Azemiglitazone (2-5 μM in blood, p.o.) causes weight loss and suppresses stellate cell activation with or without MPC function in HTF-C diet feeding LS-Mpc2-/-C57BL6/J mice[4].
| Animal Model: | HTF-C diet feeding C57BL6/J mice [4] |
| Dosage: | 331 ppm MSDC-0602 potassium salt (2-5 μM Azemiglitazone in blood) |
| Administration: | oral administration for 12 weeks (after 4 weeks of HTF-C diet) or 3 weeks (16 weeks after HTF-C diet) |
| Result: | Induced weight loss, decreased concentrations of plasma ALT and AST and stellate cell activation. |
| Animal Model: | HTF-C diet feeding LS-Mpc2-/-C57BL6/J mice [4] |
| Dosage: | 331 ppm MSDC-0602 potassium salt (2-5 μM Azemiglitazone in blood) |
| Administration: | oral administration for 12 weeks (after 4 weeks of HTF-C diet) |
| Result: | Induced weight loss, suppressed stellate cell activation. |
| Animal Model: | diet induced obesity C57BL/6 mice[6] |
| Dosage: | 300 ppm MSDC-0602 (2-5 μM Azemiglitazone in blood) |
| Administration: | oral administration for 2-4 weeks |
| Result: | Reduced insulin concentration in plasma, increased glucose infusion rate and glucose uptake into gastrocnemius, adipose tissue, and heart.
Improved mitochondrial oxygen consumption. |
